Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
| 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — | |
Byondis B.V.Private | 1 asset: 1 Ph 1 | BYON4413Phase 1 · Acute Myeloid Leukemia | None on record | — | — | — | — |
Cajal TherapeuticsPrivate | 1 asset: 1 Ph 1 | CTX001 (Cajal)Phase 1 · Chronic Kidney Disease | None on record | — | — | — | — |
Calico Life Sciences LLCPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | FosigotifatorPhase 2/3 | Nov 2027Fosigotifator · Phase 1/2 | — | — | — | — |
Calliditas TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | Mar 2027Budesonide (targeted-release) · Approved | — | $75MJun 2024 | ~16.9 qtrs | $50M |
cAMPfield TherapeuticsPrivate | 1 asset: 1 Ph 3 | Prifemilast (HPP737)Phase 3 · PsoriasisPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | RAD101Phase 2 · Brain Metastases | None on record | — | — | — | — | |
Candid TherapeuticsPrivate | 3 assets: 3 Ph 1 | cizutamigPhase 1 · Systemic Lupus Erythematosus | 1 Jun 2027CND261 · Phase 1 | — | — | — | — |
| 1 asset: 1 other | CAP-003Parkinson's Disease | None on record | — | — | — | — | |
Cardior Pharmaceuticals GmbHPrivate | 1 asset: 1 Ph 2 | CDR132LPhase 2 · Heart FailureWeak signal | 31 Dec 2026CDR132L · Phase 1 | — | — | — | — |
Cardurion PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | TovinontrinePhase 2 · Heart FailurePartial signal | None on record | — | — | — | — |
Carrick Therapeutics LimitedPrivate | 1 asset: 1 Ph 2 | SamuraciclibPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signal | None on record | — | — | — | — |
CatalYm GmbHPrivate | 1 asset: 1 Ph 2 | VisugromabPhase 2 · Non-Small Cell Lung CancerWeak signal | 30 Apr 2028Visugromab · Phase 1/2 | — | — | — | — |
Celavie Biosciences, LLCPrivate | 1 asset: 1 Ph 1 | OK99Phase 1 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | SENTI-301APhase 1 · Hepatocellular Carcinoma | None on record | — | — | — | — | |
Celgene CorporationPrivate | 3 assets: 2 approved, 1 Ph 2 | OnatasertibPhase 2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
CellCentric Ltd.Private | 1 asset: 1 Ph 3 | InobrodibPhase 3 · Multiple Myeloma | 31 Mar 2027Inobrodib · Phase 1/2 | — | — | — | — |
Cenna BiosciencesPrivate | 1 asset: 1 Ph 1 | 8M2DPhase 1 · Alzheimer's Disease | Sep 20278M2D · Phase 1 | — | — | — | — |
CephalonPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | TricaprilinPhase 3 · Alzheimer's DiseasePartial signal | Jan 2030Tricaprilin · Phase 3 | — | — | — | — | |
CerevancePrivate | 1 asset: 1 Ph 3 | Solengepras (CVN424)Phase 3 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | Somatropin (Jintropin)Phase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | DA-302168SPhase 3 · ObesityPartial signal | 12 Dec 2026DA-302168S · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 2 | ZhibitaiPhase 2 · Atherosclerotic Cardiovascular Disease | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | YogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 2 | Purinostat MesylatePhase 3 · Diffuse Large B-Cell Lymphoma | 15 Dec 2026Purinostat Mesylate · Phase 1 | — | — | — | — | |
| 11 assets: 11 approved | Approved assets only | None on record | — | — | — | — | |
| 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | LanifibranorPhase 3 · MASH / NASHPartial signal | None on record | — | — | — | — | |
Chiesi FarmaceuticiPrivate | 7 assets: 4 approved, 1 Ph 3, 2 Ph 2 | Beclomethasone dipropionate/formoterol fumaratePhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal | Oct 2027pegunigalsidase alfa · Phase 2/3 | — | — | — | — |
| 3 assets: 2 Ph 2, 1 Ph 1 | CD123 targeted CAR-NK cellsPhase 1/2 · Acute Myeloid LeukemiaWeak signal | 31 Dec 2026BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech) · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | LiafensinePhase 2 · Major Depressive DisorderReliable signal | None on record | — | — | — | — | |
Cirius TherapeuticsPrivate | 1 asset: 1 Ph 2 | AzemiglitazonePhase 2 · Type 2 Diabetes | None on record | — | — | — | — |
CKD Bio CorporationPrivate | 1 asset: 1 other | L. lactis CKDB001Alzheimer's Disease | 31 May 2027L. lactis CKDB001 · Phase na | — | — | — | — |
Clasp Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CLSP-5282Phase 1 · Non-Small Cell Lung Cancer | May 2029CLSP-5282 · Phase 1 | — | — | — | — |
Clexio BiosciencesPrivate | 1 asset: 1 Ph 2 | Esketamine (CLE-100)Phase 2 · Major Depressive DisorderPartial signal | None on record | — | — | — | — |
ClinectPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
CNX TherapeuticsPrivate | 1 asset: 1 Ph 3 | NabiximolsPhase 3 · Multiple SclerosisPartial signal | None on record | — | — | — | — |
Concerto BiosciencesPrivate | 1 asset: 1 Ph 1 | ENS-002Phase 1 · Atopic DermatitisWeak signal | None on record | — | — | — | — |
ConjuChemPrivate | 1 asset: 1 Ph 3 | AlbenatidePhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | CPO301Phase 3 · Non-Small Cell Lung Cancer | May 2027CPO301 · Phase 1 | — | — | — | — | |
ConSynance TherapeuticsPrivate | 1 asset: 1 Ph 2 | CSTI-500Phase 2 · Prader-Willi SyndromeWeak signal | Jun 2027CSTI-500 · Phase 2 | — | — | — | — |
CordavisPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
CoRegen, Inc.Private | 1 asset: 1 Ph 2 | CRG-150Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | Jun 2029CRG-150 · Phase 1/2 | — | — | — | — |
CorrectSequence TherapeuticsPrivate | 1 asset: 1 Ph 1 | CS-121Phase 1 · Familial Chylomicronemia Syndrome | Dec 2026CS-121 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | KRAS-specific Autologous TCR-T cellPhase 1 · Non-Small Cell Lung Cancer | 30 Nov 2028KRAS-specific Autologous TCR-T cell · Phase 1 | — | — | — | — | |
Corsera HealthPrivate | 1 asset: 1 Ph 1 | COR-1004Phase 1 · Atherosclerotic Cardiovascular Disease | Feb 2027COR-1004 · Phase 1 | — | — | — | — |
Corteria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | Corteria COR-1167Phase 2 · Heart Failure | Jul 2027Corteria COR-1167 · Phase 2 | — | — | — | — |
Corxel PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | Omecamtiv mecarbilPhase 3 · Heart FailureReliable signal | Sep 2027Omecamtiv mecarbil · Phase 3 | — | — | — | — |
Cosette PharmaceuticalsPrivate | 4 assets: 3 approved, 1 Ph 2 | bremelanotidePhase 2 · ObesityReliable signal | None on record | — | — | — | — |
CREATE MedicinesPrivate | 2 assets: 2 Ph 1 | MT-302Phase 1 · Non-Small Cell Lung Cancer | 31 Jan 2027MT-304 · Phase 1 | — | — | — | — |
Crossbow Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CBX-250Phase 1 · Acute Myeloid Leukemia | Jan 2027CBX-250 · Phase 1 | — | — | — | — |
CSL BehringPrivate | 1 asset: 1 approved | Approved assets only | 4 Oct 2028etranacogene dezaparvovec · Phase 3 | — | — | — | — |
CSL SeqirusPrivate | 2 assets: 2 approved | Approved assets only | Apr 2027Epinephrine · Approved | — | — | — | — |
| 1 asset: 1 Ph 3 | Sutantatug envedotinPhase 3 · Cervical Cancer | 16 Jan 2027Sutantatug envedotin · Phase 1/2 | — | — | — | — | |
CSPC Ouyi Pharmaceutical Co.Private | 1 asset: 1 Ph 3 | SYHX1901Phase 3 · PsoriasisPartial signal | 28 Apr 2027SYHX1901 · Phase 3 | — | — | — | — |
| 4 assets: 4 Ph 3 | stapokibartPhase 3 · Atopic DermatitisReliable signal | 25 Dec 2026Docetaxel (HB1801) · Phase 2 | — | — | — | — | |
Cullgen (Shanghai),IncPrivate | 1 asset: 1 Ph 1 | CG009301Phase 1 · Acute Myeloid Leukemia | 30 Dec 2027CG009301 · Phase 1 | — | — | — | — |
Cyclarity TherapeuticsPrivate | 1 asset: 1 Ph 1 | UDP-003Phase 1 · Atherosclerotic Cardiovascular Disease | 30 Dec 2026UDP-003 · Phase 1 | — | — | — | — |
Cycle Pharmaceuticals Ltd.Private | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | ISC-hpNSCPhase 1 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 1 | SDT-M001Phase 1 · Non-Small Cell Lung Cancer | 26 Jun 2027SDT-M001 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 2 | CTS2190Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
DalCor PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | DalcetrapibPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | Aug 2027Dalcetrapib · Phase 3 | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | 31 May 2027Tovorafenib · Phase 2 | — | — | — | — | |
DebiopharmPrivate | 1 asset: 1 Ph 2 | Debio 1562MPhase 1/2 · Acute Myeloid Leukemia | None on record | — | — | — | — |
Debiopharm International SAPrivate | 1 asset: 1 Ph 2 | ZedoresertibPhase 1/2 · HR+/HER2- Metastatic Breast Cancer | Dec 2027Zedoresertib · Phase 1 | — | — | — | — |
DEKA BiosciencesPrivate | 1 asset: 1 Ph 1 | DK210Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Denovo BiopharmaPrivate | 1 asset: 1 Ph 2 | LiafensinePhase 2 · Major Depressive DisorderReliable signal | None on record | — | — | — | — |
Dermavon HoldingsPrivate | 1 asset: 1 Ph 3 | CMS-D001Phase 2/3 · Psoriasis | 31 Jan 2027CMS-D001 · Phase 2 | — | — | — | — |
Desitin Arzneimittel GmbHPrivate | 1 asset: 1 Ph 3 | Piribedil (Clarium)Phase 3 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
DeuterOncologyPrivate | 1 asset: 1 Ph 1 | DO-2Phase 1 · Non-Small Cell Lung Cancer | Sep 2027DO-2 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 3 | LepodisiranPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | Mar 2027Lepodisiran · Phase 1 | — | — | — | — | |
Direct BiologicsPrivate | 1 asset: 1 Ph 2 | ExoFloPhase 2 · Crohn's DiseaseWeak signal | Jun 2027ExoFlo · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 2 | HEC88473Phase 2 · Type 2 DiabetesWeak signal | None on record | — | — | — | — | |
Dracen PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | SirpiglenastatPhase 2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Draig TherapeuticsPrivate | 1 asset: 1 Ph 2 | DT-101Phase 2 · Major Depressive Disorder | May 2027DT-101 · Phase 2 | — | — | — | — |
Dren BioPrivate | 1 asset: 1 Ph 1 | DR-0202Phase 1 · Non-Small Cell Lung Cancer | Jul 2027DR-0202 · Phase 1 | — | — | — | — |
EA PharmaPrivate | 1 asset: 1 Ph 3 | UpacicalcetPhase 3 · Chronic Kidney DiseasePartial signal | 22 Feb 2032Upacicalcet · Phase 3 | — | — | — | — |
EccogenePrivate | 2 assets: 1 Ph 3, 1 Ph 2 | elecoglipronPhase 3 · ObesityReliable signal | Dec 2026ECC4703 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | EDP167Phase 2 · Atherosclerotic Cardiovascular DiseaseWeak signal | Nov 2027EDP167 · Phase 2 | — | — | — | — | |
Edgewood Oncology Inc.Private | 1 asset: 1 Ph 1 | BTX-A51Phase 1 · Acute Myeloid Leukemia | None on record | — | — | — | — |
EHL BioPrivate | 1 asset: 1 Ph 3 | ADSTEMPhase 3 · Atopic Dermatitis | Sep 2029ADSTEM · Phase 3 | — | — | — | — |
EicOsis Human Health, Inc.Private | 1 asset: 1 Ph 2 | EC5026Phase 1/2 · Parkinson's Disease | Dec 2026EC5026 · Phase 1/2 | — | — | — | — |
Elevar Therapeutics, Inc.Private | 3 assets: 1 approved, 2 Ph 3 | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Jul 2027Apatinib · Phase 2 | — | — | — | — |
Elion Oncology, Inc.Private | 1 asset: 1 Ph 2 | EniluracilPhase 2 · Metastatic Colorectal Cancer | None on record | — | — | — | — |
Elixiron ImmunotherapeuticsPrivate | 1 asset: 1 Ph 2 | EnrupatinibPhase 2 · Alzheimer's Disease | Aug 2027Enrupatinib · Phase 1 | — | — | — | — |
Ellipses PharmaPrivate | 3 assets: 3 Ph 2 | LunbotinibPhase 1/2 · Non-Small Cell Lung Cancer | 31 Dec 2026Lunbotinib · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 3 | OrdastobartPhase 2/3 · Head and Neck Squamous Cell Carcinoma | 28 Feb 2027Ordastobart · Phase 2 | — | — | — | — | |
EMD SeronoPrivate | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Empros PharmaPrivate | 1 asset: 1 Ph 2 | Orlistat/acarbose (EMP16)Phase 2 · ObesityReliable signal | None on record | — | — | — | — |
Encoded Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | ETX101Phase 1/2 · Epilepsy | Jun 2028ETX101 · Phase 1/2 | — | — | — | — |
Encore DermatologyPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
EncuraGenPrivate | 1 asset: 1 other | (PEG)-BHD1028Obesity | None on record | — | — | — | — |
Engrail TherapeuticsPrivate | 1 asset: 1 Ph 1 | ENX-104Phase 1 · Major Depressive DisorderWeak signal | None on record | — | — | — | — |
Enterin Inc.Private | 1 asset: 1 Ph 2 | ENT-01Phase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
Enveda TherapeuticsPrivate | 1 asset: 1 Ph 2 | ENV-294Phase 2 · Atopic DermatitisWeak signal | Dec 2026ENV-294 · Phase 2 | — | — | — | — |
Enyo PharmaPrivate | 1 asset: 1 Ph 2 | VonafexorPhase 2 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
EpiBiologicsPrivate | 1 asset: 1 Ph 1 | EPI-326Phase 1 · Non-Small Cell Lung Cancer | Jul 2029EPI-326 · Phase 1 | — | — | — | — |
EpiDestinyPrivate | 1 asset: 1 Ph 2 | Decitabine/Tetrahydrouridine (NDec)Phase 2 · Sickle Cell Disease | None on record | — | — | — | — |
EpiEndo PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | glasmacinalPhase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.